Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3). https://doi.org/10.1542/peds.2017-1904.

Cheung EL, Bell CS, Samuel JP, Poffenbarger T, Redwine KM, Samuels JA. Race and obesity in adolescent hypertension. Pediatrics. 2017;139(5). https://doi.org/10.1542/peds.2016-1433.

•  Bell CS, Samuel JP, Samuels JA. Prevalence of hypertension in children. Hypertension. 2019;73(1):148–52. https://doi.org/10.1161/HYPERTENSIONAHA.118.11673. This study highlights the increase in prevalance of hypertension in children based on the 2017 Clinical Practice Guidelines.

Sharma AK, Metzger DL, Rodd CJ. Prevalence and severity of high blood pressure among children based on the 2017 American Academy of Pediatrics Guidelines. JAMA Pediatr. 2018;172(6):557–65. https://doi.org/10.1001/jamapediatrics.2018.0223.

Article  PubMed  PubMed Central  Google Scholar 

Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for high blood pressure in children and adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(18):1878–83. https://doi.org/10.1001/jama.2020.20122.

Article  PubMed  Google Scholar 

Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008;117(25):3171–80. https://doi.org/10.1161/circulationaha.107.730366.

Article  PubMed  PubMed Central  Google Scholar 

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13. https://doi.org/10.1016/s0140-6736(02)11911-8.

Article  PubMed  Google Scholar 

Leiba A, Twig G, Levine H, Goldberger N, Afek A, Shamiss A, et al. Hypertension in late adolescence and cardiovascular mortality in midlife: a cohort study of 2.3 million 16- to 19-year-old examinees. Pediatr Nephrol. 2016;31(3):485–92. https://doi.org/10.1007/s00467-015-3240-1.

Brady TM, Fivush B, Flynn JT, Parekh R. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr. 2008;152(1):73–8, 8.e1. https://doi.org/10.1016/j.jpeds.2007.05.053.

McNiece KL, Gupta-Malhotra M, Samuels J, Bell C, Garcia K, Poffenbarger T, et al. Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension. 2007;50(2):392–5. https://doi.org/10.1161/hypertensionaha.107.092197.

CAS  Article  PubMed  Google Scholar 

Kollias A, Dafni M, Poulidakis E, Ntineri A, Stergiou GS. Out-of-office blood pressure and target organ damage in children and adolescents: a systematic review and meta-analysis. J Hypertens. 2014;32(12):2315–31; discussion 31. https://doi.org/10.1097/hjh.0000000000000384.

•  Du T, Fernandez C, Barshop R, Chen W, Urbina EM, Bazzano LA. 2017 Pediatric hypertension guidelines improve prediction of adult cardiovascular outcomes. Hypertension. 2019;73(6):1217–23. https://doi.org/10.1161/hypertensionaha.118.12469. This study highlights that children who were reclassified into a higher blood pressure category based on the 2017 Clinical Practice Guidelines were more likely to have hypertension and other comorbidities as adults. This links pediatric blood pressure to important comorbidities later in life.

••  Urbina EM, Mendizábal B, Becker RC, Daniels SR, Falkner BE, Hamdani G, et al. Association of blood pressure level with left ventricular mass in adolescents. Hypertension. 2019;74(3):590-6. https://doi.org/10.1161/HYPERTENSIONAHA.119.13027. This study found that some adolescents develop LVH despite having blood pressure measurements well below the 95th percentile. This highlights the importance of screening for pediatric hypertension as end organ damage can be seen even before meeting blood pressures classified as hypertensive.

Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl. 2005;23(1):S27-33. https://doi.org/10.1097/01.hjh.0000165625.79933.9a.

CAS  Article  PubMed  Google Scholar 

Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16(11 Pt 1):895–9. https://doi.org/10.1016/s0895-7061(03)01018-5.

Article  PubMed  Google Scholar 

Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95–110. https://doi.org/10.1093/ajh/5.2.95.

Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003. https://doi.org/10.1016/s0140-6736(02)08089-3.

Article  PubMed  Google Scholar 

Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41–6. https://doi.org/10.1016/s0002-9343(03)00158-x.

Article  PubMed  Google Scholar 

Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol. 2007;28(1):27–33. https://doi.org/10.1007/s00246-006-1390-4.

Article  PubMed  Google Scholar 

Kupferman JC, Paterno K, Mahgerefteh J, Pagala M, Golden M, Lytrivi ID, et al. Improvement of left ventricular mass with antihypertensive therapy in children with hypertension. Pediatr Nephrol. 2010;25(8):1513–8. https://doi.org/10.1007/s00467-010-1511-4.

Article  PubMed  Google Scholar 

Yang L, Magnussen CG, Bovet P, Xi B. Elevated blood pressure in childhood or adolescence and cardiovascular outcomes in adulthood: a systematic review. Hypertension. 2020;75(4):948–55. https://doi.org/10.1161/hypertensionaha.119.14168.

CAS  Article  PubMed  Google Scholar 

Day TG, Park M, Kinra S. The association between blood pressure and carotid intima-media thickness in children: a systematic review. Cardiol Young. 2017;27(7):1295–305. https://doi.org/10.1017/s1047951117000105.

Article  PubMed  Google Scholar 

Lona G, Endes K, Köchli S, Infanger D, Zahner L, Hanssen H. Retinal vessel diameters and blood pressure progression in children. Hypertension. 2020;76(2):450–7. https://doi.org/10.1161/hypertensionaha.120.14695.

CAS  Article  PubMed  Google Scholar 

Lande MB, Batisky DL, Kupferman JC, Samuels J, Hooper SR, Falkner B, et al. Neurocognitive function in children with primary hypertension. J Pediatr. 2017;180:148-55.e1. https://doi.org/10.1016/j.jpeds.2016.08.076.

Article  PubMed  Google Scholar 

Lande MB, Batisky DL, Kupferman JC, Samuels J, Hooper SR, Falkner B, et al. Neurocognitive function in children with primary hypertension after initiation of antihypertensive therapy. J Pediatr. 2018;195:85-94.e1. https://doi.org/10.1016/j.jpeds.2017.12.013.

Article  PubMed  PubMed Central  Google Scholar 

Rovio SP, Raitakari OT. Reply: Cardiovascular risk factors from childhood and midlife cognitive performance. J Am Coll Cardiol. 2017;70(15):1946–7. https://doi.org/10.1016/j.jacc.2017.07.791.

Article  PubMed  Google Scholar 

Ostrovskaya MA, Rojas M, Kupferman JC, Lande MB, Paterno K, Brosgol Y, et al. Executive function and cerebrovascular reactivity in pediatric hypertension. J Child Neurol. 2015;30(5):543–6. https://doi.org/10.1177/0883073813494264.

Article  PubMed  Google Scholar 

Snauwaert E, Vande Walle J, De Bruyne P. Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review. Arch Dis Child. 2017;102(1):63–71. https://doi.org/10.1136/archdischild-2016-310582.

Article  PubMed  Google Scholar 

Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics. 1985;75(6):1091–100.

CAS  Article  Google Scholar 

Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800.

CAS  Article  Google Scholar 

Raes A, Malfait F, Van Aken S, France A, Donckerwolcke R, Vande WJ. Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children. J Renin Angiotensin Aldosterone Syst. 2007;8(1):3–12. https://doi.org/10.3317/jraas.2007.004.

CAS  Article  PubMed  Google Scholar 

Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42(8):870–80.

CAS  Article  Google Scholar 

Menon S, Berezny KY, Kilaru R, Benjamin DK Jr, Kay JD, Hazan L, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J. 2006;152(2):394–9. https://doi.org/10.1016/j.ahj.2005.12.025.

CAS  Article  PubMed  Google Scholar 

Seeman T, Dusek J, Vondrak K, Flogelova H, Geier P, Janda J. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. Am J Hypertens. 2004;17(5 Pt 1):415–20. https://doi.org/10.1016/j.amjhyper.2004.01.008.

CAS  Article  PubMed  Google Scholar 

Soergel M, Verho M, Wühl E, Gellermann J, Teichert L, Schärer K. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol. 2000;15(1–2):113–8. https://doi.org/10.1007/s004670000422.

CAS  Article  PubMed  Google Scholar 

Wuhl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66(2):768–76. https://doi.org/10.1111/j.1523-1755.2004.00802.x.

Article  PubMed  Google Scholar 

Burrello J, Erhardt EM, Saint-Hilary G, Veglio F, Rabbia F, Mulatero P, et al. Pharmacological treatment of arterial hypertension in children and adolescents: a network meta-analysis. Hypertension. 2018;72(2):306–13. https://doi.org/10.1161/hypertensionaha.118.10862.

CAS  Article  PubMed  Google Scholar 

Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18(2 Pt 1):183–90. https://doi.org/10.1016/j.amjhyper.2004.09.009.

CAS  Article  PubMed  Google Scholar 

Franks AM, O’Brien CE, Stowe CD, Wells TG, Gardner SF. Candesartan cilexetil effectively reduces blood pressure in hypertensive children. Ann Pharmacother. 2008;42(10):1388–95. https://doi.org/10.1345/aph.1L212.

CAS  Article  PubMed  Google Scholar 

Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich). 2008;10(10):743–50. https://doi.org/10.1111/j.1751-7176.2008.00022.x.

CAS  Article  Google Scholar 

Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28(5):1083–90. https://doi.org/10.1097/HJH.0b013e328336b86b.

CAS  Article  PubMed  Google Scholar 

Flynn JT, Meyers KE, Neto JP, de Paula MR, Zurowska A, Bagga A, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52(2):222–8. https://doi.org/10.1161/HYPERTENSIONAHA.108.111054.

CAS  Article  PubMed  Google Scholar 

Lou-Meda R, Stiller B, Antonio ZL, Zielinska E, Yap HK, Kang HG, et al. Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension. Pediatr Nephrol. 2019;34(3):495–506. https://doi.or